Cinclus Pharma Holding AB (FRA:J8P) OCF Margin %: -952.68% (As of Mar. 2026)


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €0.96
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB OCF Margin %?

Cinclus Pharma Holding AB FRA:J8P -1.23% 6 OCF Margin % is -952.68% as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 959 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 94.47% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Cinclus Pharma Holding AB's Cash Flow from Operations for the three months ended in Mar. 2026 was €-8.88 Mil. Cinclus Pharma Holding AB's Revenue for the three months ended in Mar. 2026 was €0.93 Mil. Therefore, Cinclus Pharma Holding AB's OCF Margin % for the quarter that ended in Mar. 2026 was -952.68%.

As of today, Cinclus Pharma Holding AB's current OCF Yield % is -24.01%.

The historical rank and industry rank for Cinclus Pharma Holding AB's OCF Margin % or its related term are showing as below:

FRA:J8P' s OCF Margin % Range Over the Past 10 Years
Min: -3894.48   Med: -2663.72   Max: -129.89
Current: -193.32

During the past 5 years, the highest OCF Margin % of Cinclus Pharma Holding AB was -129.89%. The lowest was -3894.48%. And the median was -2663.72%.

FRA:J8P's OCF Margin % is ranked worse than
94.47% of 959 companies
in the Drug Manufacturers industry
Industry Median: 9.94 vs FRA:J8P: -193.32

Cinclus Pharma Holding AB OCF Margin % Related Terms

Cinclus Pharma Holding AB OCF Margin % Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB OCF Margin % Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 -1,816.22 -3,508.63 -3,896.23 -129.88

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 187.53 -480.70 -366.32 -952.68

FRA:J8P vs ZTS: OCF Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cinclus Pharma Holding AB OCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Cinclus Pharma Holding AB's OCF Margin % falls into.


FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Cinclus Pharma Holding AB's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.859/5.281
=-129.88 %

Cinclus Pharma Holding AB's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-8.879/0.932
=-952.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of -952.68% mean?
Cinclus Pharma Holding AB (FRA:J8P) has a OCF Margin % of -952.68% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #906 out of 959 companies in the Drug Manufacturers industry, placing it in the top 94.5%.
Is Cinclus Pharma Holding AB's OCF Margin % too high?
Cinclus Pharma Holding AB's current OCF Margin % is -952.68%. Based on the distribution chart, Cinclus Pharma Holding AB ranks #906 out of 959 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #906 out of 959 companies for OCF Margin %. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median OCF Margin % is 9.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current OCF Margin % is -952.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current OCF Margin % of -952.68%. The current OCF Margin % is -952.68%. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current OCF Margin % is -952.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price